Literature DB >> 31004000

A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer.

Felipe de Sousa E Melo1, Omar Kabbarah2, Robert Piskol3, Ling Huw4, Ismail Sergin5, Christiaan Kljin6, Zora Modrusan7, Doris Kim2, Noelyn Kljavin5, Rachel Tam2, Rajesh Patel2, Jeremy Burton5, Elicia Penuel2, Xueping Qu2, Hartmut Koeppen8, Teiko Sumiyoshi2, Frederic de Sauvage7, Mark R Lackner2.   

Abstract

PURPOSE: Four consensus molecular subtypes (CMS1-4) of colorectal cancer were identified in primary tumors and found to be associated with distinctive biological features and clinical outcomes. Given that distant metastasis largely accounts for colorectal cancer-related mortality, we examined the molecular and clinical attributes of CMS in metastatic colorectal cancer (mCRC). EXPERIMENTAL
DESIGN: We developed a colorectal cancer-focused NanoString-based CMS classifier that is ideally suited to interrogate archival tissues. We successfully used this panel in the CMS classification of formalin-fixed paraffin-embedded (FFPE) tissues from mCRC cohorts, one of which is composed of paired primary tumors and metastases. Finally, we developed novel mouse implantation models to enable modeling of colorectal cancer in vivo at relevant sites.
RESULTS: Using our classifier, we find that the biological hallmarks of mCRC, including CMS, are in general highly similar to those observed in nonmetastatic early-stage disease. Importantly, our data demonstrate that CMS1 has the worst outcome in relapsed disease, compared with other CMS. Assigning CMS to primary tumors and their matched metastases reveals mostly concordant subtypes between primary and metastasis. Molecular analysis of matched discordant pairs reveals differences in stromal composition at each site. The development of two novel in vivo orthotopic implantation models further reinforces the notion that extrinsic factors may impact on CMS identification in matched primary and metastatic colorectal cancer.
CONCLUSIONS: We describe the utility of a NanoString panel for CMS classification of FFPE clinical samples. Our work reveals the impact of intrinsic and extrinsic factors on colorectal cancer heterogeneity during disease progression. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31004000     DOI: 10.1158/1078-0432.CCR-18-3032

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  21 in total

Review 1.  The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.

Authors:  Javier Ros; Iosune Baraibar; Giulia Martini; Francesc Salvà; Nadia Saoudi; José Luis Cuadra-Urteaga; Rodrigo Dienstmann; Josep Tabernero; Elena Élez
Journal:  Curr Treat Options Oncol       Date:  2021-11-06

2.  Validation of Anticorrelated TGFβ Signaling and Alternative End-Joining DNA Repair Signatures that Predict Response to Genotoxic Cancer Therapy.

Authors:  Ines Guix; Qi Liu; Miquel Angel Pujana; Patrick Ha; Josep Piulats; Isabel Linares; Ferran Guedea; Jian-Hua Mao; Ann Lazar; Jocelyn Chapman; Sue S Yom; Alan Ashworth; Mary Helen Barcellos-Hoff
Journal:  Clin Cancer Res       Date:  2022-04-01       Impact factor: 13.801

Review 3.  Biomarker-guided therapy for colorectal cancer: strength in complexity.

Authors:  Anita Sveen; Scott Kopetz; Ragnhild A Lothe
Journal:  Nat Rev Clin Oncol       Date:  2019-07-09       Impact factor: 66.675

4.  Early Adaptation of Colorectal Cancer Cells to the Peritoneal Cavity Is Associated with Activation of "Stemness" Programs and Local Inflammation.

Authors:  Jorge Barriuso; Raghavendar T Nagaraju; Shreya Belgamwar; Bipasha Chakrabarty; George J Burghel; Helene Schlecht; Lucy Foster; Elaine Kilgour; Andrew J Wallace; Michael Braun; Caroline Dive; D Gareth Evans; Robert G Bristow; Mark P Saunders; Sarah T O'Dwyer; Omer Aziz
Journal:  Clin Cancer Res       Date:  2020-11-30       Impact factor: 12.531

5.  Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging.

Authors:  Esther Strating; Emma Wassenaar; Mathijs Verhagen; Paulien Rauwerdink; Susanne van Schelven; Ignace de Hingh; Inne Borel Rinkes; Djamila Boerma; Arjen Witkamp; Miangela Lacle; Riccardo Fodde; Richard Volckmann; Jan Koster; Kris Stedingk; Frederik Giesel; Remmert de Roos; Alex Poot; Guus Bol; Marnix Lam; Sjoerd Elias; Onno Kranenburg
Journal:  Br J Cancer       Date:  2022-03-16       Impact factor: 9.075

6.  Development of a miRNA-based classifier for detection of colorectal cancer molecular subtypes.

Authors:  Ronja S Adam; Dennis Poel; Leandro Ferreira Moreno; Joey M A Spronck; Tim R de Back; Arezo Torang; Patricia M Gomez Barila; Sanne Ten Hoorn; Florian Markowetz; Xin Wang; Henk M W Verheul; Tineke E Buffart; Louis Vermeulen
Journal:  Mol Oncol       Date:  2022-04-29       Impact factor: 7.449

Review 7.  Exploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges.

Authors:  Joyce Y Buikhuisen; Arezo Torang; Jan Paul Medema
Journal:  Oncogenesis       Date:  2020-07-09       Impact factor: 7.485

8.  The DNA hypermethylation phenotype of colorectal cancer liver metastases resembles that of the primary colorectal cancers.

Authors:  Stephany Orjuela; Mirco Menigatti; Peter Schraml; Patryk Kambakamba; Mark D Robinson; Giancarlo Marra
Journal:  BMC Cancer       Date:  2020-04-06       Impact factor: 4.430

9.  Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer.

Authors:  Peter W Eide; Seyed H Moosavi; Ina A Eilertsen; Tuva H Brunsell; Jonas Langerud; Kaja C G Berg; Bård I Røsok; Bjørn A Bjørnbeth; Arild Nesbakken; Ragnhild A Lothe; Anita Sveen
Journal:  NPJ Genom Med       Date:  2021-07-14       Impact factor: 8.617

10.  Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Sanne Ten Hoorn; Tim R de Back; Dirkje W Sommeijer; Louis Vermeulen
Journal:  J Natl Cancer Inst       Date:  2022-04-11       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.